Rheumatoid arthritis


RHEUMATOID ARTHRITIS

The DSU has written reports for a number of NICE Technology Appraisals in the disease area rheumatoid arthritis (RA):


ADALIMUMAB, ETANERCEPT, INFLIXIMAB, CERTOLIZUMAB PEGOL, GOLIMUMAB, ABATACEPT AND TOCILIZUMAB

NICE Appraisal

Rheumatoid arthritis – adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab [in progress, ID537]

DSU Report

Progression of disease in people with rheumatoid arthritis treated with non biologic therapies (February 2015)

Further documents on this Technology Appraisal can be accessed here, including the DSU’s response to comments on the above report.


TOCILIZUMAB (RAPID REVIEW)

NICE Appraisal

TA247 Tocilizumab for the treatment of rheumatoid arthritis (rapid review of TA198) (February 2012)

DSU Report

Tocilizumab for the treatment of rheumatoic arthritis (September 2011)


TOCILIZUMAB

NICE Appraisal

TA198 Tocilizumab for the treatment of rheumatoid arthritis (August 2010) replaced by TA247

DSU Report

Tocilizumab for the treatment of rheumatoid arthritis (May 2010)


ADALIMUMAB, ETANERCEPT AND INFLIXIMAB (SEQUENTIAL USE)

NICE Appraisal

Rheumatoid arthritis – adalimumab, etanercept and infliximab (sequential use) (suspended)

DSU Reports

Sequential TNF-a inhibitors and non biologic DMARDs – analysis of the national databank for rheumatic diseases (March 2008)

The sequential use of TNF-a inhibitors – update to a report by the decision support unit (January 2008)

The effectiveness of non biologic DMARDs after anti TNF-a inhibitor failure (January 2008)

Related publication

S Lloyd, S Bujkiewicz, A Wailoo, A Sutton, D Scott. The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 2010; Vol 49 (12): 2313-2321.


ADALIMUMAB, ETANERCEPT AND INFLIXIMAB

NICE Appraisal

TA130 Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (October 2007)

DSU Report

Sequential use of TNF-a inhibitors for the treatment of rheumatoid arthritis (August 2006)